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Acute otitis media is an extremely common disease, most children being subject t o  it once or more during their first 
5 years of life. Thirty t o  forty per cent of episodes of acute otitis media are caused by Streptococcus pneumoniae. 
Resistance of pneumococci to antibiotics is an increasing problem particularly in France. Since 1983 a 23-valent 
pneumococcal polysaccharide vaccine has been available, containing in particular four serotypes that carry penicillin 
resistance. Unfortunately, this vaccine is therefore not fully effective until after the age of 2 years. In spite of good 
serologic responses, clinical results have been variable. Some found that this diminished frequency only lasted for 
several months and ended as serotypes not included in the 23-valent vaccines began to  appear. Since 1992, studies have 
been carried out using different pneumococcal vaccines conjugated to diphtheria, tetanus or meningococcal proteins. 
Despite the incomplete nature of the data, it can already be confirmed that these vaccines are immunogenic from the 
very first months of life onwards. Numerous problems nevertheless remain unsolved. How many serotypes can be 
included in the conjugate vaccine? For the moment it seems technically impossible to conjugate all 23 serotypes of the 
current vaccine. While Haemophilus influenzae type b is principally responsible for invasive infections, it is traditionally 
said to play only a minor role in  otitis, which is usually provoked by non-capsulated Haemophilus strains beyond the 
vaccine’s reach. In fact, in  most studies it has been observed that 2-5% of cases of Haemophilus otitis are due to 
Haemophilus type b. The vaccine could be said, therefore, t o  have a minor but by no means negligible role in the 
prevention of Haemophilus otitis. In conclusion, pneumococcal and haemophilus vaccines have not revolutionized the 
preventive treatment of otitis for the moment, but great hopes are still placed on the conjugate pneumococcal vaccine. 
Key words: Otitis media, pneumococcal vaccine, haemophilus vaccine 
The justification for using bacterial vaccines against 
otitis media is based on four types of information. 
1 .  Children develop specific antibodies after the 
administration of bacterial vaccine or bacterial in- 
fection. 
2. A later episode of otitis media in a child with 
recurrent otitis is rarely due to a strain of bacteria 
that caused the earlier episode. 
3. Relatively few serotypes are responsible for most 
episodes of pneumococcal otitis (4,19,23,9,3); con- 
versely, the data regarding serotypes of sequential 
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episodes due to Haemoplzilrrr injluenzae are inconi- 
plete. 
4. Experience with pneumococcal vaccine indicated 
that children >2 years who developed type-specific 
antibodies had type-specific protection against new 
episodes of otitis media [l]. 
ANTIPNEUMOCOCCAL VACCINE 
Acute otitis media is an extremely common disease, 
most children being subject to it once or more during 
their first 5 years of life; 30-40% of episodes of 
acute otitis niedia are caused by Stveptococcus pneuinoniae. 
Thus, in the USA, the C D C  estimates the annual 
incidence of pneumococcal otitis as between 7 000 000 
and 10 000 000 cases. Auditive sequelae, and their 
consequences for development, are often severe. And 
one cannot avoid recalling the role of pneumococcal 
otitis media in triggering pneumococcal meningitis. 
Resistance of pneumococci to antibiotics is an 
increasing problem; in France, for example, resistance 
3s59 
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to P-lactamines has grown from 0.5% in 1984 to 30% 
according to region, especially for the pneumococci 
responsible for otitis [2]. Of  all the strains with 
abnormal sensitivity to P-lactamines, 84.4% belong to 
four serotypes: 6, 14, 19 and 23. Worse still, resistance 
is by no means confined to the P-lactamines, but also 
affects macrolides, tetracyclines and cotrimoxazole. 
Finally, it is a worldwide phenomenon, encountered 
especially in the under-5s. Under such conditions, 
prevention by vaccination ought to be playing a 
predominant role. 
Since 1983, a 23-valent pneumococcal polysac- 
charide vaccine has been available, containing in parti- 
cular four serotypes which carry penicillin resistance: 
6, 14, 19 and 23. 
Unfortunately, this vaccine is so-called ‘thymo- 
independent’, and is therefore not fully effective until 
after the age of 2 years. Above this age, 82% of 
vaccinated subjects multiplied their pre-vaccination 
antibody titers by at least two. Below it, the immune 
response in healthy children is mediocre, varying 
mainly as a function of the polysaccharide serotype. 
In children vaccinated at 6 months, the response 
is relatively good for serotypes 3, 18 and 4. From 12 
months onwards, it becomes good for more serotypes. 
Certain polysaccharides [3,4,8] induce effective im- 
munity at  any age. Finally, serotypes 6, 19 and 23 
provoke no immune response at all. This ineffectiveness 
before the age of 2 years is, of course, a major 
drawback, the peak frequency of pneumococcal otitis 
media occurring around the age of 1 year [3]. 
What about the effectiveness of pneumococcal vaccine 
after the age of 2 years? 
Despite good serologic responses, clinical results have 
been variable, Several randomized controlled trials have 
assessed the effectiveness of pneumococcal vaccines 
against otitis media: Douglas, in a study of 1158 healthy 
Australian children, noted no consistent differences 
between vaccines and controls in the mean number 
of episodes of otitis [4]. Other studies of otitis-prone 
children younger than 2 years have been mixed [S]. 
A recent study of 320 children in Finland reported 
a 51% reduction in recurrent otitis but a later study 
showed a negligible effect [6].  
Another report indicated that black but not white 
children 6-11 months of age had significantly fewer 
recurrences of AOM. The reason for the apparent effect 
of race is unknown. 
In conclusion, from the results of these studies, 
pneumococcal vaccines (23V) are not indicated before 
2 years but may be of value for older children who are 
still suffering from recurrent episodes of AOM. 
Some found that this diminished frequency lasted 
for several months, and ended as serotypes not included 
in the 23-valent vaccine began to appear. 
Because of the increasing resistance of S. pneu- 
moniae, a more aggressive use of the vaccine is warranted. 
The future of pneumococcal vaccines 
Since 1992, studies have been carried out using different 
pneumococcal vaccines conjugated to diphtheria, 
tetanus or meningococcal proteins. Despite the in- 
complete nature of the data, it can already be con- 
firmed that these vaccines are immunogenic from the 
very first months of life onwards. They induce serocon- 
version consistently better than the classic poly- 
saccharide vaccines, and do so whatever the age at  
vaccination. 
Recent data suggest (ICAAC 95): 
1. That oropharyngeal carriage of S. pneumoniae is 
2. That polysaccharide-diphtheria conjugate vac-cine 
3. And finally that safety is a problem if conjugate 
lower after conjugate vaccine [7]. 
is more immunogenic [8]. 
vaccine contains more than six serotypes [8]. 
Numerous problems nevertheless remain unsolved. 
How many serotypes can be included in the conjugate 
vaccine? For the moment it seems technically im- 
possible to conjugate all 23 serotypes of the current 
vaccine. Such a combination would require injection 
of a large volume of vaccine and would provoke in- 
tolerable local and general reactions. The cost of the 
vaccine would also be considerably increased. There 
would seem to be no choice but to limit the vaccine to 
the 6, 8 or 10 serotypes that are the most frequent, the 
most pathogenic, and especially the most often resistant 
to penicillin. The present tendency therefore favors 
vaccines containing serotypes 6, 14, 19 and 23, and also 
1, 5 and 18. Theoretically, such combinations should 
be modified according to regional epidemiologic data. 
Very recently it has been demonstrated that the strong 
antigenicity of these conjugate vaccines allows doses 
to be reduced, which should allow the number of 
serotypes to be increased without going above 10. 
For the moment it is difficult to be sure that no 
shift will occur, with the emergence of serotypes not 
included in the conjugate vaccine. 
The same doubt applies to the penicillin-resistant 
serotypes which, as already mentioned, are for the 
moment mainly limited to serotypes 6, 14, 19 and 23. 
In conclusion, in the race between the emergence 
of a multiresistant strain and the development of the 
new antipneumococcal vaccine, it is too early to pick 
the likely winner. 
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HAEMOPHILUS TYPE B VACCINE 
In a recent French study it was shown that Huerno- 
philus represents 42% of AOM. While Huemophilus 
injuenzue type b is principally responsible for invasive 
infections (meningitis, epiglottitis, septicemia, etc.), it 
is traditionally said to play only a minor role in otitis, 
which is usually provoked by non-capsulated Huemo- 
philus strains beyond the vaccine’s reach. 
In fact, in most studies it has been observed that 
2-596 of cases of Huemophilus otitis are due to Huemo- 
philus type b. The vaccine could be said, therefore, to 
have a minor but by no means negligible role in the 
prevention of Huemophilus otitis [9]. 
In practice, this fact exerts a considerable influence 
on the prescriber’s antibiotic strategy. 
In a child under 5 years old with acute otitis media 
who has not been vaccinated against Huemophilus type 
b, prescription of an antibiotic that is active against 
Huemophilus is mandatory to avoid the possibility of 
secondary bacterial meningitis. Because levels of p- 
lactamase-producing Huemophilus strains are high, the 
choice of antibiotic will be more restricted. O n  the 
other hand, for a child in the same situation who has 
received the Huemophilus type b vaccine, the risk of 
meningitis is non-existent; and since it is well estab- 
lished that otitis due to non-capsulated Huemophilus 
strains never leads to serious complications, the major 
imperative will instead be to treat a possible pneumo- 
coccal otitis. 
This shows just how much a child’s vaccination 
status can modify the rules for prescribing antibiotics. 
Finally, we might add that a recent study by the CDC 
(ICAAC 93) [lo] showed that children vaccinated 
against Huemophilus type b were less likely to have 
recurrent otitis. Such a result, for which there is no 
explanation at present, requires confirmation. 
In conclusion, pneumococcal and Huemophilus 
vaccines have not revolutionized the preventive treat- 
ment of otitis for the moment, but great hopes are still 
placed on the conjugate pneumococcal vaccine. 
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